<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03803761</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2019-00048</org_study_id>
    <secondary_id>NCI-2019-00048</secondary_id>
    <secondary_id>NCI10195</secondary_id>
    <secondary_id>10195</secondary_id>
    <secondary_id>10195</secondary_id>
    <secondary_id>UM1CA186704</secondary_id>
    <nct_id>NCT03803761</nct_id>
  </id_info>
  <brief_title>A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer</brief_title>
  <official_title>A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and how well copanlisib works when given&#xD;
      together with fulvestrant in treating patients with estrogen receptor positive (ER+) and&#xD;
      human epidermal growth factor receptor 2 negative (HER2-) breast cancer that has spread to&#xD;
      other places in the body (advanced) and progressing after prior treatment. HER2 and ER are&#xD;
      two types of proteins called receptors that can affect the growth of breast cancer cells.&#xD;
      Additionally, investigators hope to learn from this study if tumor genetic information is&#xD;
      important for predicting whether this type of breast cancer will respond to fulvestrant and&#xD;
      copanlisib. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking&#xD;
      the use of estrogen by the tumor cells. Giving copanlisib and fulvestrant may work better in&#xD;
      treating patients with ER+ and HER2- breast cancer compared to fulvestrant alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Establish safety of the combination of copanlisib and fulvestrant (FC). II. Evaluate the&#xD;
      response rate (RR) of the combination of copanlisib and fulvestrant in patients with&#xD;
      estrogen-receptor positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative&#xD;
      metastatic breast cancer that has previously progressed on aromatase inhibitor (AI)/cyclin&#xD;
      dependent kinase (CDK) 4/6 inhibitor therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate progression-free survival (PFS) in patients treated with copanlisib and&#xD;
      fulvestrant stratifying by actionable PIK3CA mutation, actionable PIK3CA or PTEN mutation, or&#xD;
      wild type PIK3CA and PTEN.&#xD;
&#xD;
      II. Estimate the RR in subjects with PTEN loss by immunohistochemistry (IHC) analysis&#xD;
      performed retrospectively.&#xD;
&#xD;
      III. Evaluate toxicity in patients treated with FC in Phase II.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate copanlisib pharmacokinetics (PK) when given in combination with fulvestrant.&#xD;
&#xD;
      II. Explore association between intrinsic subtype and response to FC therapy. III. Assess&#xD;
      baseline levels and treatment-induced proteomic changes and correlate with response to FC.&#xD;
&#xD;
      IV. Evaluate circulating tumor deoxyribonucleic acid (DNA) (ctDNA) mutations at baseline and&#xD;
      over time for response predictors at baseline, clonal evolution associated with treatment,&#xD;
      and resistance mechanisms at disease progression.&#xD;
&#xD;
      V. Evaluate PFS in patients with baseline ctDNA PIK3CA actionable mutations versus (vs.)&#xD;
      those with wild type PK3CA.&#xD;
&#xD;
      VI. To evaluate genomic and gene expression changes in tumor cells and in associated tumor&#xD;
      microenvironment before and after administration of copanlisib in combination with&#xD;
      fulvestrant and at the time of progression.&#xD;
&#xD;
      VII. Evaluate circulating markers of metabolism before and after PI3K inhibitor therapy which&#xD;
      may predict treatment response and resistance mechanisms.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive copanlisib intravenously (IV) over 1 hour on days 1, 8, and 15 and&#xD;
      fulvestrant intramuscularly (IM) over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1&#xD;
      beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Inadequate accrual rate&#xD;
  </why_stopped>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Actual">February 19, 2022</completion_date>
  <primary_completion_date type="Actual">February 19, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Toxicities will be tabulated based on type and grade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From start of treatment to time of progression or death, assessed up to 30 days post treatment</time_frame>
    <description>PFS will be estimated using the Kaplan Meier method, with median and 95% confidence interval (CI) reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Response rate will be reported for subjects with PTEN loss by immunohistochemistry (IHC) analysis performed retrospectively. This will be done across cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Toxicities will be tabulated based on type and grade. Any toxicity seen in more than 10% of patients will be reported, and all grade 3-4 toxicities will be reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics (PK) and pharmacodynamic data (RPPA)</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Descriptive statistics will be provided.</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers analysis</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>Prognostic effect of biomarker for PFS will be examined by the Kaplan Meier (KM) method or/and Cox proportional hazard model and for objective response rate (ORR) using logistic regression model. Predictive effect of biomarker will be explored by examining the interaction effect of biomarker and arm in Cox or logistic regression model. For markers measured along multiple time points, generalized linear mixed effects model will be used to model longitudinal trajectories along time with the inference focus on the arm factor, without and with adjustment for other covariates. Two sample t-test or Wilcoxon rank sum test will be applied to compare time-matched biomarkers between the two arms or two patient subsets. Paired sample t-test or Wilcoxon signed rank test will be applied to compare subject-specific biomarkers between two time points. Multiple comparisons will be adjusted to control false discovery rate. Proposed subset analyses will be applicable to biomarkers.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anatomic Stage IV Breast Cancer AJCC v8</condition>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Prognostic Stage IV Breast Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (copanlisib, fulvestrant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (copanlisib, fulvestrant)</arm_group_label>
    <other_name>BAY 80-6946</other_name>
    <other_name>PI3K Inhibitor BAY 80-6946</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Treatment (copanlisib, fulvestrant)</arm_group_label>
    <other_name>Faslodex</other_name>
    <other_name>Faslodex(ICI 182,780)</other_name>
    <other_name>ICI 182,780</other_name>
    <other_name>ICI 182780</other_name>
    <other_name>ZD9238</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women with estrogen receptor positive (ER+), human epidermal growth&#xD;
             factor receptor 2 (HER2) negative metastatic breast cancer (MBC) who have progressed&#xD;
             on combination therapy with an aromatase inhibitor and cyclin-dependent kinase 4/6&#xD;
             (CDK 4/6) inhibitor&#xD;
&#xD;
               -  Note: Postmenopausal females are considered of childbearing potential unless they&#xD;
                  are surgically or permanently sterile (have undergone a hysterectomy, bilateral&#xD;
                  tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal&#xD;
                  for at least 12 consecutive months. A high follicle stimulating hormone (FSH)&#xD;
                  level in the postmenopausal range may be used to confirm a post-menopausal state&#xD;
                  in women not using hormonal contraception or hormonal replacement therapy.&#xD;
                  Documentation of postmenopausal status must be provided&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1&#xD;
             (RECIST1.1)&#xD;
&#xD;
          -  Patients must have had tumor sequencing for evaluation of actionable PIK3CA or PTEN&#xD;
             mutations performed in a Clinical Laboratory Improvement Act (CLIA) certified, College&#xD;
             of American Pathologist (CAP) tested and bioinformatics-validated testing lab PRIOR to&#xD;
             enrollment in this current protocol. If available patient tumor sequencing status must&#xD;
             be provided to University of North Carolina (UNC) principal investigator (PI) at&#xD;
             consent, and prior to any additional screening procedures. The testing may have been&#xD;
             done at any time prior to enrollment. For patients who have not yet had tumor genomic&#xD;
             assessment, after consultation with the PI, tumor specimens will be sent to the UNC&#xD;
             Hospitals Clinical Molecular Genetics Laboratory for assessment of the Solid Tumor&#xD;
             Mutation Panel. In this case, results of genetic testing by the UNC lab must be&#xD;
             available prior to the first on study disease assessment (i.e., prior to day 1 of&#xD;
             cycle 4). In this case, the study will cover the cost of the Solid Tumor Panel&#xD;
&#xD;
          -  Female subjects who are not of childbearing potential&#xD;
&#xD;
               -  Note: Because no dosing or adverse event data are currently available on the use&#xD;
                  of copanlisib in combination with fulvestrant in patients &lt;18 years of age, and&#xD;
                  only postmenopausal women with ER+/HER2 negative MBC are eligible or appropriate&#xD;
                  for treatment with fulvestrant, children and pregnant or pre-menopausal women are&#xD;
                  excluded from this study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  No prior treatment history with fulvestrant or a PI3K inhibitor&#xD;
&#xD;
          -  Subject has not received more than 2 prior lines of chemotherapy in the metastatic&#xD;
             setting&#xD;
&#xD;
          -  Subject must have washout period from prior systemic anti-cancer therapy of at least&#xD;
             21 days (or 5 half-lives of the systemic anti-cancer therapy, whichever is shorter)&#xD;
             before the start of study treatment&#xD;
&#xD;
          -  Subject must have washout period from prior radiation therapy of at least 2 weeks&#xD;
             before the start of study treatment&#xD;
&#xD;
          -  Subjects with a history of brain metastases are allowed if they are not on steroid&#xD;
             therapy and there is no evidence of intracranial disease progression symptomatically&#xD;
             or by imaging within 28 days prior to study registration&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL (collected no more than 7 days before starting&#xD;
             treatment)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (collected no more than 7 days&#xD;
             before starting treatment) (&lt; 3 x ULN for patients with Gilbert syndrome, patients&#xD;
             with cholestasis due to compressive adenopathies of the hepatic hilum or documented&#xD;
             liver involvement)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal (ULN) OR =&lt; 5 x institutional ULN if&#xD;
             liver metastases present (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &gt;= 60 mL/min/1.73 m^2 unless data exists supporting&#xD;
             safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 (collected&#xD;
             no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Fasting blood glucose &lt; 120 mg/dL (collected no more than 7 days before starting&#xD;
             treatment)&#xD;
&#xD;
          -  Lipase =&lt; 1.5 x ULN (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  International normalized ratio (INR) and partial thromboplastin time (PTT) =&lt; 1.5 x&#xD;
             ULN (collected no more than 7 days before starting treatment)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50%&#xD;
&#xD;
          -  Subject must agree to provide archival tumor material for research and/or agree to&#xD;
             undergo a tumor biopsy for research if the tumor is accessible for biopsy prior to&#xD;
             study treatment&#xD;
&#xD;
          -  Ability to understand and the willingness to comply with study procedures and to sign&#xD;
             a written informed consent document&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous assignment to treatment during this study. Patients permanently withdrawn&#xD;
             from study participation will not be allowed to re-enter the study&#xD;
&#xD;
          -  Concomitant participation in another clinical study with investigational medicinal&#xD;
             product&#xD;
&#xD;
          -  Subjects who have not recovered from adverse events due to prior anti-cancer therapy&#xD;
             (i.e., have residual toxicities &gt; grade 1) with the exception of alopecia&#xD;
&#xD;
          -  Immunosuppressive therapy is not allowed while on study&#xD;
&#xD;
          -  Subjects who are receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to copanlisib, fulvestrant, or PI3K inhibitors&#xD;
&#xD;
          -  Subjects with moderate or severe hepatic impairment (ie, Child-Pugh B or C)&#xD;
&#xD;
          -  Copanlisib is primarily metabolized by CYP3A4. Therefore, the concomitant use of&#xD;
             strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin,&#xD;
             ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYP3A4 (e.g.&#xD;
             rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) are not permitted&#xD;
             from 14 days prior to enrollment until the end of the study. Other medications that&#xD;
             are prohibited while on copanlisib treatment:&#xD;
&#xD;
               -  Herbal medications/preparations (except for vitamins)&#xD;
&#xD;
               -  Anti-arrhythmic therapy other than beta blockers or digoxin&#xD;
&#xD;
          -  Systemic corticosteroid therapy at a daily dose higher than 15 mg prednisone or&#xD;
             equivalent is not permitted while on study. Previous corticosteroid therapy must be&#xD;
             stopped or reduced to the allowed dose at least 7 days prior to the computed&#xD;
             tomography (CT)/magnetic resonance imaging (MRI) screening; if a patient is on chronic&#xD;
             corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed&#xD;
             dose before the screening; patients may be using topical or inhaled corticosteroids;&#xD;
             short-term (up to 7 days) systemic corticosteroids above 15 mg prednisolone or&#xD;
             equivalent will be allowed for the management of acute conditions (e.g., treatment&#xD;
             non-infectious pneumonitis); the use of corticosteroids as antiemetics prior to&#xD;
             copanlisib administration will not be allowed&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury (as judged by the&#xD;
             investigator) within 28 days prior to start of treatment, or not recovered from major&#xD;
             side effects, or open biopsy within 7 days before start of study treatment&#xD;
&#xD;
          -  Patients with non-healing wound, ulcer, or bone fracture not due to breast cancer&#xD;
&#xD;
          -  Patients with active, clinically serious infections &gt; grade 2 (Common Terminology&#xD;
             Criteria for Adverse Events [CTCAE] version [v]5.0)&#xD;
&#xD;
          -  Patients with glycosylated hemoglobin (HbA1c) &gt; 8.5% at screening&#xD;
&#xD;
          -  Proteinuria of &gt;= CTCAE grade 3 as assessed by a 24 hour (h) protein quantification or&#xD;
             estimated by urine protein: creatinine ratio &gt; 3.5 on a random urine sample&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within 3 months before the start of study medication&#xD;
&#xD;
          -  Congestive heart failure &gt; New York Heart Association (NYHA) class 2&#xD;
&#xD;
               -  Note: Class III NYHA Heart failure classification: Patients with cardiac disease&#xD;
                  resulting in marked limitation of physical activity. They are comfortable at&#xD;
                  rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or&#xD;
                  anginal pain&#xD;
&#xD;
               -  Note: Class IV NYHA Heart failure classification: Patients with cardiac disease&#xD;
                  resulting in the inability to carry on any physical activity without discomfort.&#xD;
                  Symptoms of heart failure or the anginal syndrome may be present even at rest. If&#xD;
                  any physical activity is undertaken, discomfort is increased.&#xD;
&#xD;
        Other cardiovascular-related abnormalities or therapy that prohibit study participation&#xD;
        are:&#xD;
&#xD;
          -  Myocardial infarction less than 6 months before start of study medications&#xD;
&#xD;
          -  Unstable angina (angina symptoms at rest), new onset angina (begun within the last 3&#xD;
             months)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension despite optimal medical management&#xD;
&#xD;
          -  Anti-arrhythmic therapy (exceptions: beta blockers or digoxin are permitted)&#xD;
&#xD;
               -  Pregnant or lactating (Pregnant women or women who are breastfeeding are excluded&#xD;
                  from this study because copanlisib is a PI3K inhibitor agent with the potential&#xD;
                  for teratogenic or abortifacient effects; there is no safety data in pregnancy;&#xD;
                  because there is an unknown but potential risk for adverse events in nursing&#xD;
                  infants secondary to treatment of the mother with copanlisib, breastfeeding&#xD;
                  should be discontinued if the mother is treated with copanlisib and/or&#xD;
                  fulvestrant; fulvestrant may also cause fetal harm and based on animal studies,&#xD;
                  may impair fertility in females of reproductive potential)&#xD;
&#xD;
               -  Hepatitis B virus (HBV) or hepatitis C virus (HCV). All patients must be screened&#xD;
                  for HBV and HCV up to 28 days prior to study drug start using the routine&#xD;
                  hepatitis virus lab panel; patients positive for hepatitis B virus surface&#xD;
                  antigen (HBsAg) and/or hepatitis B virus core antibody (HBcAb) will be eligible&#xD;
                  if they are negative for deoxyribonucleic acid (DNA), these patients should&#xD;
                  receive prophylactic antiviral therapy; patients positive for anti-HCV antibody&#xD;
                  will be eligible if they are negative for HCV ribonucleic acid (RNA)&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV)-positive patients on combination&#xD;
                  antiretroviral agents that are strong CYP3A4 inhibitors or inducers and who are&#xD;
                  unwilling or unable to change to antiretroviral therapies without such&#xD;
                  interactions are ineligible because of the potential for pharmacokinetic&#xD;
                  interactions with copanlisib&#xD;
&#xD;
               -  Subjects with seizure disorder requiring medication&#xD;
&#xD;
               -  Subjects with evidence or history of bleeding diathesis; any hemorrhage or&#xD;
                  bleeding event &gt;= CTCAE grade 3 within 4 weeks prior to the start of study&#xD;
                  medication&#xD;
&#xD;
               -  Blood or platelet transfusion less than 7 days before start of study treatment or&#xD;
                  myeloid growth factors within 14 days prior to treatment&#xD;
&#xD;
               -  History of concurrent condition of interstitial lung disease of any severity&#xD;
                  and/or severely impaired lung function (as judged by the investigator)&#xD;
&#xD;
               -  History of, or current autoimmune disease&#xD;
&#xD;
               -  Concurrent diagnosis of pheochromocytoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth C Dees</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University - Duke Cancer Institute LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>April 16, 2022</last_update_submitted>
  <last_update_submitted_qc>April 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03803761
org study id: NCI-2019-00048
secondary id: NCI-2019-00048
secondary id: NCI10195
secondary id: 10195
secondary id: 10195
secondary id: UM1CA186704
nct id: NCT03803761
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase I/II trial studies the side effects and how well copanlisib works when given
      together with fulvestrant in treating patients with estrogen receptor positive (ER+) and
      human epidermal growth factor receptor 2 negative (HER2-) breast cancer that has spread to
      other places in the body (advanced) and progressing after prior treatment. HER2 and ER are
      two types of proteins called receptors that can affect the growth of breast cancer cells.
      Additionally, investigators hope to learn from this study if tumor genetic information is
      important for predicting whether this type of breast cancer will respond to fulvestrant and
      copanlisib. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking
      the use of estrogen by the tumor cells. Giving copanlisib and fulvestrant may work better in
      treating patients with ER+ and HER2- breast cancer compared to fulvestrant alone.
PRIMARY OBJECTIVES:

      I. Establish safety of the combination of copanlisib and fulvestrant (FC). II. Evaluate the
      response rate (RR) of the combination of copanlisib and fulvestrant in patients with
      estrogen-receptor positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative
      metastatic breast cancer that has previously progressed on aromatase inhibitor (AI)/cyclin
      dependent kinase (CDK) 4/6 inhibitor therapy.

      SECONDARY OBJECTIVES:

      I. Estimate progression-free survival (PFS) in patients treated with copanlisib and
      fulvestrant stratifying by actionable PIK3CA mutation, actionable PIK3CA or PTEN mutation, or
      wild type PIK3CA and PTEN.

      II. Estimate the RR in subjects with PTEN loss by immunohistochemistry (IHC) analysis
      performed retrospectively.

      III. Evaluate toxicity in patients treated with FC in Phase II.

      EXPLORATORY OBJECTIVES:

      I. Evaluate copanlisib pharmacokinetics (PK) when given in combination with fulvestrant.

      II. Explore association between intrinsic subtype and response to FC therapy. III. Assess
      baseline levels and treatment-induced proteomic changes and correlate with response to FC.

      IV. Evaluate circulating tumor deoxyribonucleic acid (DNA) (ctDNA) mutations at baseline and
      over time for response predictors at baseline, clonal evolution associated with treatment,
      and resistance mechanisms at disease progression.

      V. Evaluate PFS in patients with baseline ctDNA PIK3CA actionable mutations versus (vs.)
      those with wild type PK3CA.

      VI. To evaluate genomic and gene expression changes in tumor cells and in associated tumor
      microenvironment before and after administration of copanlisib in combination with
      fulvestrant and at the time of progression.

      VII. Evaluate circulating markers of metabolism before and after PI3K inhibitor therapy which
      may predict treatment response and resistance mechanisms.

      OUTLINE:

      Patients receive copanlisib intravenously (IV) over 1 hour on days 1, 8, and 15 and
      fulvestrant intramuscularly (IM) over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1
      beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose limiting toxicity (DLT)
time frame: Up to 30 days post treatment
description: Toxicities will be tabulated based on type and grade.
measure: Progression-free survival (PFS)
time frame: From start of treatment to time of progression or death, assessed up to 30 days post treatment
description: PFS will be estimated using the Kaplan Meier method, with median and 95% confidence interval (CI) reported.
measure: Response rate
time frame: Up to 30 days post treatment
description: Response rate will be reported for subjects with PTEN loss by immunohistochemistry (IHC) analysis performed retrospectively. This will be done across cohorts.
measure: Incidence of adverse events
time frame: Up to 30 days post treatment
description: Toxicities will be tabulated based on type and grade. Any toxicity seen in more than 10% of patients will be reported, and all grade 3-4 toxicities will be reported.
measure: Pharmacokinetics (PK) and pharmacodynamic data (RPPA)
time frame: Up to 30 days post treatment
description: Descriptive statistics will be provided.
measure: Biomarkers analysis
time frame: Up to 30 days post treatment
description: Prognostic effect of biomarker for PFS will be examined by the Kaplan Meier (KM) method or/and Cox proportional hazard model and for objective response rate (ORR) using logistic regression model. Predictive effect of biomarker will be explored by examining the interaction effect of biomarker and arm in Cox or logistic regression model. For markers measured along multiple time points, generalized linear mixed effects model will be used to model longitudinal trajectories along time with the inference focus on the arm factor, without and with adjustment for other covariates. Two sample t-test or Wilcoxon rank sum test will be applied to compare time-matched biomarkers between the two arms or two patient subsets. Paired sample t-test or Wilcoxon signed rank test will be applied to compare subject-specific biomarkers between two time points. Multiple comparisons will be adjusted to control false discovery rate. Proposed subset analyses will be applicable to biomarkers.
arm group label: Treatment (copanlisib, fulvestrant)
arm group type: Experimental
description: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
intervention type: Drug
intervention name: Copanlisib
description: Given IV
arm group label: Treatment (copanlisib, fulvestrant)
other name: BAY 80-6946
other name: PI3K Inhibitor BAY 80-6946
intervention type: Drug
intervention name: Fulvestrant
description: Given IM
arm group label: Treatment (copanlisib, fulvestrant)
other name: Faslodex
other name: Faslodex(ICI 182,780)
other name: ICI 182,780
other name: ICI 182780
other name: ZD9238
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Elizabeth C Dees
role: Principal Investigator
affiliation: Duke University - Duke Cancer Institute LAO
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Breast Neoplasms
mesh term: Neoplasms
mesh term: Fulvestrant
sharing ipd: Yes
ipd description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
ipd url: https://grants.nih.gov/policy/sharing.htm